Cargando…

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma

BACKGROUND: Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the development of novel forms of therapy is urgently required. Specific immunotherapy gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hudolin, Tvrtko, Kastelan, Zeljko, Ilic, Ivana, Levarda-Hudolin, Katarina, Basic-Jukic, Nikolina, Rieken, Malte, Spagnoli, Giulio C, Juretic, Antonio, Mengus, Chantal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663708/ https://www.ncbi.nlm.nih.gov/pubmed/23680437 http://dx.doi.org/10.1186/1479-5876-11-123

Ejemplares similares

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study
por: Matković, Božica, et al.
Publicado: (2011)

Bone morphogenic proteins-2, −4, −6 and 7 in non-muscle invasive bladder cancer
por: Hudolin, Tvrtko, et al.
Publicado: (2020)

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

LAPAROSCOPIC RADICAL PROSTATECTOMY: SINGLE CENTER CASE SERIES
por: Penezić, Luka, et al.
Publicado: (2022)

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018)

Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
por: Freiberger, Sandra N., et al.
Publicado: (2022)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

Senhance robot-assisted adrenalectomy: a case series
por: Knežević, Nikola, et al.
Publicado: (2022)

Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells
por: Pagotto, Anna, et al.
Publicado: (2013)

Extraperitoneal radical prostatectomy with the Senhance Surgical System robotic platform
por: Kaštelan, Željko, et al.
Publicado: (2019)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

PELVIC REHABILITATION FOR URINARY INCONTINENCE AFTER RADICAL PROSTATECTOMY
por: Hudolin, Tvrtko, et al.
Publicado: (2022)

Immunohistochemical Expression of Wnt-4 Protein in Clear Cell Renal Carcinoma
por: Pavlovic, Oliver, et al.
Publicado: (2021)

THE PROSTATE CENTER: MULTIDISCIPLINARITY, ORGANIZATION OF DIAGNOSTIC WORK-UP AND TREATMENT OF PROSTATE CANCER
por: Kuliš, Tomislav, et al.
Publicado: (2019)

Targeted prostate biopsy using a cognitive fusion of multiparametric magnetic resonance imaging and transrectal ultrasound in patients with previously negative systematic biopsies and non-suspicious digital rectal exam
por: Kuliš, Tomislav, et al.
Publicado: (2020)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
por: Bujas, T., et al.
Publicado: (2011)

Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

ANESTHESIA FOR ROBOT-ASSISTED RADICAL PROSTATECTOMY - A CHALLENGE FOR ANAESTHESIOLOGIST
por: Bačak Kocman, Iva, et al.
Publicado: (2022)

SENHANCE ROBOTIC RADICAL PROSTATECTOMY
por: Kuliš, Tomislav, et al.
Publicado: (2022)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
por: Ishihara, Mikiya, et al.
Publicado: (2020)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

MAGE-A Antigens and Cancer Immunotherapy
por: Zajac, Paul, et al.
Publicado: (2017)

Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression
por: Hou, Zhenbo, et al.
Publicado: (2020)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma
por: Ueda, Shugo, et al.
Publicado: (2018)

Histopathological Features of Time-Zero Kidney Biopsy Are Predictive Factors for Posttransplant Anemia
por: Mokos, Mislav, et al.
Publicado: (2023)

Transient expression of the cancer/testis cancer antigen NY-ESO-1 in Nicotiana benthamiana using a PVX-based viral vector
por: Lacorte, Cristiano, et al.
Publicado: (2014)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
por: Shiohama, Yasuo, et al.
Publicado: (2017)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Characterization of highly frequent epitope-specific CD45RA(+)/CCR7(+/- )T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors
por: Provenzano, Maurizio, et al.
Publicado: (2006)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
por: Gjerstorff, Morten F, et al.
Publicado: (2013)

NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens
por: Schultz-Thater, E, et al.
Publicado: (2000)

Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A
por: Pourmaleki, Maryam, et al.
Publicado: (2019)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jvcr6p591t8o4fur9n57ukg9am